Archives
-
CCK8 Workflows for LNP Cell Viability Studies
2026-09-16
Use CCK8 to distinguish formulation-related cytotoxicity from changes in cellular metabolic activity during mRNA LNP development. This practical workflow connects Cell Counting Kit-8 readouts with biodistribution and transgene-expression questions without treating viability data as a substitute for pharmacokinetic or expression measurements.
-
Cell Counting Kit-8 (CCK-8) Plus Protocol Guide
2026-09-15
Cell Counting Kit-8 (CCK-8) Plus provides a rapid WST-8-based colorimetric readout for estimating viable-cell abundance in proliferation, cytotoxicity, and drug screening workflows. It should be used as a metabolic viability measurement within a validated linear range, not as a direct cell counter or a standalone proof of a specific cell-death mechanism.
-
Ionizing Radiation Rewires Neuronal Differentiation
2026-09-14
The reference study shows that ionizing radiation does more than reduce neural stem-cell viability: it drives an altered neuronal differentiation program in C17.2 cells through PI3K-linked STAT3–mGluR1 and p53 signaling. Its combination of morphological, molecular, pharmacological, and primary-cell evidence provides a useful framework for studying how radiotherapy may disrupt later neural function.
-
Ceruletide Workflows for Pancreatic Fibrosis Research
2026-09-14
Ceruletide, also known as Caerulein, provides a controllable CCK-receptor challenge for pancreatic injury, secretion, and gastrointestinal motility experiments. This guide connects practical reagent handling with fibrosis-focused readouts inspired by recent MFGE8–ANXA1–SMAD2/3 research.
-
Dual HER2–VEGFR2 Targeting in TNBC
2026-09-13
A 2026 study examined lapatinib and Telatinib (BAY 57-9352) in HER2-negative MDA-MB-231 triple-negative breast cancer cells. The combination reduced proliferation, invadopodia formation, and two-dimensional angiogenic tube formation, while also highlighting the mechanistic and translational limits of inferring HER2/VEGFR2 target engagement from phenotype alone.
-
Persistent rDNA Damage and PML-Nucleolar Compartments
2026-09-12
The reference study identifies persistent ribosomal DNA lesions, rather than generic genotoxicity alone, as a trigger for PML-nucleolar associations. By combining topological-stress treatments, targeted I-PpoI cleavage, repair-pathway perturbation, and imaging of DNA-repair markers, it provides a mechanistic framework linking rDNA damage, incomplete homologous recombination, nucleolar compartmentalization, and senescence.
-
Prochlorperazine Workflows for Antiemetic and Cancer Researc
2026-09-10
Prochlorperazine combines dopamine D2 receptor antagonism with experimentally useful effects on melanoma phenotypes and viral entry pathways. This practical guide converts those properties into reproducible dosing, migration, cytotoxicity, and time-of-addition workflows while separating established evidence from hypothesis-generating applications.
-
Cholecystokinin octapeptide ammonium Assay Guide
2026-09-10
Build more reproducible CCK receptor experiments with a workflow that connects receptor activation to ROS, PGC-1α, PPAR signaling, ANP release, and behavioral or cellular endpoints. This guide emphasizes sulfation-aware controls, concentration selection, handling of an insoluble peptide, and troubleshooting across cardiac, neuronal, immune, and behavioral models.
-
Resazurin Cell Viability Assay Kit for Bone Research
2026-09-09
The Resazurin Cell Viability Assay Kit provides a sensitive, non-toxic way to quantify living cells by fluorescence or colorimetry, making it useful for dose-response studies and high-throughput screening. In skeletal disease research, it can complement pathway, differentiation, and imaging endpoints without replacing mechanistic validation.
-
Resazurin Cell Viability Assay in Sclerosteosis
2026-09-09
Learn how the Resazurin Cell Viability Assay Kit can separate cell-health effects from osteogenic efficacy in Wnt-driven sclerosteosis research. This article develops an assay strategy grounded in PORCN inhibition, metabolic readout limitations, and orthogonal bone endpoints.
-
Maridomycin Study: Leucomycin Activity and Resistance
2026-09-08
The reference study established a broad phenotypic profile for maridomycin by combining susceptibility testing, resistance selection, serum-binding analysis, bactericidal measurements, and mouse infection models. Its main practical contribution was to connect in vitro antibacterial behavior with therapeutic activity while showing both cross-resistance among macrolides and activity against selected resistant staphylococci.
-
Cholecystokinin Octapeptide Ammonium: Mechanism
2026-09-08
Cholecystokinin octapeptide ammonium, also called CCK-8 ammonium, is a sulfated brain–gut peptide reagent that engages CCK1R and CCK2R signaling. Evidence in morphine-withdrawal rats supports a CCK1R-dependent reduction of anxiety-like behavior, while product documentation describes broader concentration-dependent neuroendocrine, immune, apoptotic, and cardiovascular research uses.
-
Luminescent ATP Cell Viability Assay Kit I in Ferroptosis
2026-09-07
Learn how the Luminescent ATP Cell Viability Assay Kit I converts intracellular ATP into a rapid, sensitive viability readout for ferroptosis research. This guide focuses on interpreting ATP loss mechanistically, designing controls, and translating luciferase luminescence detection into reliable cytotoxicity data.
-
PP 1: Mechanistic Validation of Cancer Biomarkers
2026-09-07
PP 1 is a Src family tyrosine kinase inhibitor suited to testing whether imaging- and pathology-derived cancer phenotypes have functional signaling correlates. This article presents a biomarker-to-perturbation workflow grounded in multimodal gastric cancer research, with practical assay controls and limitations.
-
0.4% Trypan Blue Solution: Practical Guide
2026-09-05
0.4% Trypan Blue Solution provides a direct visual method for separating viable cells from dead or membrane-damaged cells during cell counting and cell viability measurement. It is intended for scientific research workflows, including cytotoxicity assays, and should not be used for diagnostic or medical purposes.